BrainStorm Cell Therapeutics Prepares Phase 3b ALS Trial

CEO Chaim Lebovits confirmed that the company is finalizing operational requirements to enroll approximately 200 patients in the upcoming trial. The study design includes a 24-week double-blind, placebo-controlled phase followed by an open-label extension, with results intended to support a future Biologics License Application.

To bolster its regulatory and commercial efforts, the company appointed Peter J. Pitts as Executive Chairman. Pitts, a former FDA Associate Commissioner, will oversee daily operations and investor engagement, while longtime Board Chairman Professor Jacob Frenkel transitions to a senior advisor role. Financially, BrainStorm reported cash and cash equivalents of approximately $0.2 million as of June 30, 2026. The company raised $400,000 through private placements in the second quarter, bringing total capital raised in the first half of the year to $2.4 million.